Our earliest capture with readable facts. This is our first observation, not when the company introduced these things. These website claims are not independently verified.
biotechnology company developing antibodies targeting receptors that modulate the activity of immune effector cells involved in inflammation and tissue damage
All facts above belong to this capture. Unlisted fields mean we have no readable observation, not that they were absent.
How it describes itself
Similar headlines are grouped together. The quote shown is from the last capture in each group, not necessarily the exact wording throughout that period.
February 2024 – April 2025 · 3 captures · latest observed messagingAllakos │ Therapeutic antibodies │ Mast cells and Eosinophils
Allakos is developing therapeutic antibodies that selectively target eosinophils and mast cells, cells that play a significant role in many diseases